Consensus recommendations from the american acne and rosacea society on the management of rosacea, part 2: A status report on topical agents

Cutis

Volumn 92, Issue 6, 2013, Pages 277-284

  Del Rosso, James Q ^a,b   Thiboutot, Diane ^c   Gallo, Richard ^d   Webster, Guy ^e   Tanghetti, Emil ^f   Eichenfield, Larry ^g,h   Stein Gold, Linda ⁱ   Berson, Diane ^j   Zaenglein, Andrea ^c  

^a TOURO UNIVERSITY NEVADA   (United States)

^b West Dermatology Group   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f Center for Dermatology and Laser Surgery   (United States)

^g RADY CHILDREN'S HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HENRY FORD HOSPITAL   (United States)

^j NEW YORK PRESBYTERIAN HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT;

ARTICLE; CONSENSUS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MEDICAL SOCIETY; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; ROSACEA; SKIN CARE; UNITED STATES;

ADMINISTRATION, CUTANEOUS; CONSENSUS; DERMATOLOGIC AGENTS; DRUG APPROVAL; HUMANS; PRACTICE GUIDELINES AS TOPIC; ROSACEA; SKIN CARE; SOCIETIES, MEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84891644234     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Del Rosso JQ, Baldwin H, Webster G; American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7:531-533.
2. Del Rosso JQ, Gallo RL, Tanghetti E, et al. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91(suppl 3):1-8.
3. Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol. 2012;5:26-36.
4. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol. 2008;1:20-25.
5. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
6. Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol. 2012;5:16-25.
7. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004;51:499-512; quiz 513-514.
8. Metrogel 1% [package insert]. Fort Worth, TX: Galderma Laboratories; 2011.
9. Finacea Gel 15% [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2012.
10. Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 2: options according to rosacea subtype. Cutis. 2009;84:97-104.
11. Elewski B, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450.
12. McClellan KJ, Noble S. Topical metronidazole. a review of its uses in rosacea. Am J Clin Dermatol. 2000;1:191-199.
13. Liu RH, Smith MK, Basta SA, et al. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142:1047-1052.
14. Kennedy Carney C, Cantrell W, Elewski BE. Rosacea: a review of current topical, systemic and light-based therapies. G Ital Dermatol Venereol. 2009;144:673-688.
15. Del Rosso JQ, Bhatia N. Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application. Cutis. 2011;88:67-72.
16. Conde JF, Yelverton CB, Balkrishnan R, et al. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol. 2007;6:495-498.
17. van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev. 2011;3:CD003262.
18. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004;73(suppl 1):29-33.
19. Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8:299-304.
20. Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel [published online ahead of print July 18, 2013]. J Am Acad Dermatol. 2013;69:570-577.
21. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
22. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(suppl 4):3-11.
23. Rosina P, Zamperetti M, Giovannini A, et al. Videocapillaroscopic alterations in erythematotelangiectatic rosacea [published online ahead of print November 11, 2005]. J Am Acad Dermatol. 2006;54:100-104.
24. Draelos ZD. Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel. Cutis. 2004;74:257-260.
25. Yoo J, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol. 2006;5:317-319.
26. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, et al. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7:541-546.
27. Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol. 2012;11:838-844.
28. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641-645.
29. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
30. Thiboutot DM, Fleischer AB, Del Rosso JQ, et al. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8:639-648.
31. Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. J Drugs Dermatol. 2005;4:585-590.
32. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9:607-613.
33. Del Rosso JQ. Effectiveness and safety of doxycycline mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. Cutis. 2010;86(suppl 5):16-25.
34. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:573-576.
35. Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 1: overview and broad spectrum of care. Cutis. 2009;84:43-47.
36. Torok HM. Rosacea skin care. Cutis. 2000;66(suppl 4):14-16.
37. Draelos ZD. Treating beyond the histology of rosacea. Cutis. 2004;74(suppl 3):28-31.
38. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(suppl 1):26-34.
39. Levin J, Miller R. A guide to the ingredients and potential benefits of over-the-counter cleansers and moisturizers for rosacea patients. J Clin Aesthet Dermatol. 2011;4:31-49.
40. Schlesinger TE, Powell CR. Efficacy and tolerability of low molecular weight hyaluronic acid salt 0.2% cream in rosacea. J Drugs Dermatol. 2013;12:664-667.
41. Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus 1% cream for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol. 2007;156:728-732.
42. Karabulut AA, Izol Serel B, Eksioglu HM. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea[published online ahead of print March 3, 2008]. J Eur Acad Dermatol Venereol. 2008;22:729-734.
43. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed. 2005;4:147-150.
44. Koca R, Altinyazar HC, Ankarali H, et al. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial [published online ahead of print July 6, 2009]. Clin Exp Dermatol. 2010;35:251-256.
45. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004;50:107-108.
46. Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial [published online ahead of print March 20, 2008]. Br J Dermatol. 2008;158:1069-1076.
47. Chu CY. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.J Eur Acad Dermatol Venereol. 2007;21:484-490.
48. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44:995-998.
49. McHugh RC, Rice A, Sangha ND, et al. A topical azithromycin preparation for treatment of acne vulgaris and rosacea. J Dermatolog Treat. 2004;15:295-302.
50. Mills OH Jr, Kligman AM. Letter: topically applied erythromycin in rosacea. Arch Dermatol. 1976;112:553-554.
51. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-67.
52. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(suppl 6):9-25.
53. Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol. 2011;10:724-733.
54. Oztürkcan S, Emertcan A, Sahin M, et al. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol. 2004;31:610-617.
55. Breneman D, Savin R, VandePol C, et al. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-387.
56. Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis. 2004;73(suppl 6):11-17.
57. Koçak M, Yaǧli S, Vahapoǧlu G, et al. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. a randomized double-blind placebo-controlled study. Dermatology. 2002;205:265-270.
58. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41(5, pt 1):775-777.
59. Larios G, Alevizos A, Perimeni D, et al. Rosacea-like demodicidosis. Lancet Infect Dis. 2008;8:804.
60. Crawford GH, Pelle MT, James WD. Rosacea: I. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341; quiz 342-344.
61. Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea [article in English, German][published online ahead of print November 8, 2010]. J Dtsch Dermatol Ges. 2011;9:21-25.
62. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15:2-11.
63. Mc Aleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144:663-671.
64. Yamasaki K, Gallo RL. The molecular pathology of rosacea [published online ahead of print May 29, 2009]. J Dermatol Sci. 2009;55:77-81.
65. Fleischer AB Jr. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol. 2011;10:614-620.
66. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324.
67. Chang AL, Alora-Palli M, Lima XT, et al. A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. J Drugs Dermatol. 2012;11:333-339.
68. Kim GK, Rosso JD. Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis. J Clin Aesthet Dermatol. 2013;6:29-35.
69. Dirschka T, Tronnier H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141.
70. Papp KA, Papp A, Dahmer B, et al. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults [published online ahead of print November 21, 2011]. J Am Acad Dermatol. 2012;67:e11-e15.
71. Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2012;5:91-97.
72. Del Rosso JQ. Management of papulopustular rosacea and perioral dermatitis with emphasis on iatrogenic causation or exacerbation of inflammatory facial dermatoses: use of doxycycline-modified release 40mg capsule once daily in combination with properly selected skin care as an effective therapeutic approach. J Clin Aesthet Dermatol. 2011;4:20-30.
73. Chen AY, Zirwas MJ. Steroid-induced rosacealike dermatitis: case report and review of the literature. Cutis. 2009;83:198-204.
74. Rappaport MJ, Rappaport V. The red skin syndromes: corticosteroid addiction and withdrawal. Expert Rev Dermatol. 2006;1:547-561.
75. Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0•5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166:633-641.
76. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective a1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143:1369-1371.
77. Rowell LB. Reflex control of the cutaneous vasculature. J Invest Dermatol. 1977;69:154-166.
78. Johnson JM, Kellogg DL Jr. Local thermal control of human cutaneous circulation [published online ahead of print June 3, 2010]. J Appl Physiol (1985). 2010;109:1229-1238.
79. Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53:319-356.
80. Hieble JP. Subclassification and nomenclature of a- and b-adrenoceptors. Curr Top Med Chem. 2007;7:129-134.
81. Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12:650-656.
82. Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical a-adrenergic receptor agonist therapy? J Am Acad Dermatol. In press.
83. Kim JH, Oh YS, Ji JH, et al. Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline [published online ahead of print November 3, 2010].J Dermatol. 2011;38:510-513.
84. Mirvaso topical gel 0.33% [package insert]. Fort Worth, TX: Galderma Laboratories, LP; 2013.
85. Fallen RS, Gooderham M. Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012;17:1-4.